Genetic Testing: Breast Cancer Gene (cont.)

Medical Author:
Medical Editor:

The whole issue of genetic testing for breast cancer is complicated. Recent research indicates that the information women seek most often when they request genetic testing does not match what they can realistically determine from this testing. Nevertheless, it is worthwhile to consider the role of this testing and what it involves.

Certain characteristics make a woman at higher risk for genetic breast cancer disorders. These factors include:

  1. family members with breast cancer, especially at a young age;
  2. breast cancer in a male family member;
  3. both breast and ovarian cancer in the family;
  4. bilateral breast cancer in a single family member;
  5. breast cancer diagnosed at very young ages; and
  6. being of Ashkenazi Jewish descent.

Ms. G. and her doctor determine that she falls within the group with higher risk factors because her sister and mother both had breast cancer at young ages.

Women at risk for a genetic breast cancer disorder must understand what the genetic testing process involves.

First, an expert reviews the family medical history to evaluate what sort of pattern of genetic breast cancer may be occurring. Next, the family member's tumor sample, if available, undergoes testing. It is impossible to run tests to analyze every single gene in a woman. Therefore, the nature of the specific disorder is narrowed by testing of the specific tumor from an affected family member. The tests are designed to determine if any of the known inherited genetic breast cancer genes is present. If the defect is found on the tissue sample of the woman's relative, the lab will then know exactly which defect should be tested in the blood sample of the woman herself. In this way, a woman will be able to be counseled about her own risk. Counseling, education, and emotional support are provided both before and after any testing, no matter what the result.

Prior to undergoing testing, it is essential that women consider the benefits and risks in light of the possible results. For example, if her test is positive (meaning she is affected by a genetic disorder) there are measures that can reduce her breast cancer risk. One of these is having breast tissue surgically removed. This is an unpleasant prospect for many women. Removal of the ovaries also appears to be helpful in reducing risk. Tamoxifen (Nolvadex) and raloxifene (Evista) are two members of the class of drugs known as selective estrogen receptor modulators (SERMs) that have been shown in clinical trials to be effective in preventing breast cancer in women at high risk for the disease, but there are fewer data available on their effects in women who are BRCA mutation carriers. There have been no studies that show that tamoxifen actually prolongs survival in women at high risk for breast cancer, and rare but serious adverse events (uterine cancer, blood clots) have been reported. Raloxifene has been tested and shown to be effective in preventing breast cancer in postmenopausal women but its effectiveness is unknown in younger women. There are no medications specifically approved for use in reducing the risk in women with genetic mutations (BRCA genes) that are known to increase susceptibility to breast cancer.

Medically Reviewed by a Doctor on 9/2/2015

Health Solutions From Our Sponsors